Product Description
Mechanisms of Action: CK2 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - MedulloblastomaOrphan Drug - Biliary Tract CancerOrphan Drug - Medulloblastoma *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Senhwa Biosciences
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Taiwan, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: COVID-19|Influenza, Human|Pneumonia
Phase 1: Basal Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CX-4945-011 | P2 |
Recruiting |
Influenza, Human|Pneumonia|COVID-19 |
2025-03-01 |
|
| CX-4945-07 | P1 |
Active, not recruiting |
Basal Cell Carcinoma |
2023-09-01 |
25% |
| CX4945-AV04-phase I | P1 |
Completed |
COVID-19 |
2023-03-23 |
70% |